RESUMEN
Toxoplasma gondii is a cosmopolitan protozoan parasite that infects a wide range of mammal and bird species. Common infection leads to high economic (e.g., abortions in sheep) and human (e.g., congenital toxoplasmosis or neurotoxoplasmosis in humans) losses. With one exception (Toxovax for sheep), there are no vaccines to prevent human or animal toxoplasmosis. The paper presents the current state and challenges in the development of a vaccine against toxoplasmosis, designed for farm animals either bred for consumption or commonly kept on farms and involved in parasite transmission. So far, the trials have mostly revolved around conventional vaccines and, compared with the research using laboratory animals (mainly mice), they have not been very numerous. However, the results obtained are promising and could be a good starting point for developing an effective vaccine to prevent toxoplasmosis.
Asunto(s)
Animales Domésticos/inmunología , Anticuerpos Antiprotozoarios/inmunología , Antígenos de Protozoos/inmunología , Vacunas Antiprotozoos/inmunología , Toxoplasma/inmunología , Toxoplasmosis Animal/prevención & control , Animales , Animales Domésticos/parasitología , Humanos , Proteínas Protozoarias/inmunología , Toxoplasma/genética , Toxoplasmosis Animal/parasitología , Toxoplasmosis Animal/transmisiónRESUMEN
Allergic asthma is a chronic inflammatory disease and despite the introduction of potent and effective drugs, the prevalence has increased substantially over the past few decades. The explanation that has attracted the most attention is the 'hygiene hypothesis', which suggests that the increase in allergic diseases is caused by a cleaner environment and fewer childhood infections. Indeed, certain mycobacterial strains can cause a shift from T-helper cell 2 (Th2) to Th1 immune responses, which may subsequently prevent the development of allergy in mice. Although the reconstitution of the balance between Th1 and Th2 is an attractive theory, it is unlikely to explain the whole story, as autoimmune diseases characterized by Th1 responses can also benefit from treatment with mycobacteria and their prevalence has also increased in parallel to allergies. Here we show that treatment of mice with SRP299, a killed Mycobacterium vaccae-suspension, gives rise to allergen-specific CD4+CD45RB(Lo) regulatory T cells, which confer protection against airway inflammation. This specific inhibition was mediated through interleukin-10 (IL-10) and transforming growth factor-beta (TGF-beta), as antibodies against IL-10 and TGF-beta completely reversed the inhibitory effect of CD4+CD45RB(Lo) T cells. Thus, regulatory T cells generated by mycobacteria treatment may have an essential role in restoring the balance of the immune system to prevent and treat allergic diseases.
Asunto(s)
Alérgenos/inmunología , Eosinofilia/inmunología , Mycobacterium/inmunología , Linfocitos T/inmunología , Traslado Adoptivo , Animales , Líquido del Lavado Bronquioalveolar/inmunología , Linfocitos T CD4-Positivos/inmunología , Eosinofilia/microbiología , Femenino , Humanos , Inmunoglobulina G/inmunología , Interferón gamma/análisis , Interleucinas/análisis , Activación de Linfocitos , Ratones , Ratones Endogámicos BALB C , Ovalbúmina/inmunología , Bazo/inmunología , Células TH1/inmunología , Células Th2/inmunología , Factor de Crecimiento Transformador beta/análisisRESUMEN
Immunization with plasmid DNA, a relatively novel technique, is a promising vaccination technique. To improve the immune response by DNA vaccination various methods have been used, such as chemical adjuvants or immunomodulatory molecules formulated into microparticles or liposomes. The aim of this research is to evaluate the immune responses of sheep immunized with DNA plasmids encoding Toxoplasma gondii dense granule antigen GRA7 formulated into three different adjuvant formulations. Sixty sheep were injected intramuscularly with the DNA plasmids. Twelve received the liposome-formulated plasmid pVAXIgGRA7, 12 Emulsigen P formulated plasmid pVAXIgGRA7 and 12 Emulsigen D formulated plasmid pVAXIgGRA7. Twelve animals were used as a control and received the vector alone. All the animals were inoculated at week 0, and week 4. Immunization of the sheep with plasmids encoding GRA7, with the different adjuvant formulations, effectively primed the immune response. After the first inoculation, moderate to high antibody responses were observed with the three different adjuvant formulations. A significantly elevated specific IgG2 response was observed in the sheep immunized with liposomes and Emulsigen D as adjuvants. In the group immunized with Emulsigen P as an adjuvant, lower IgG1 and IgG2 antibody levels were developed compared to the other treatment groups. In all the immunized groups, DNA immunization stimulated a IFN-gamma response. No antibody or IFN-gamma responses were detected in the control group immunized with an empty plasmid or not immunized. These results indicate that intramuscular immunization of sheep with a DNA vaccine with the adjuvants liposomes and Emulsigen D induce a significant immune response against T. gondii.
Asunto(s)
Anticuerpos Antiprotozoarios/biosíntesis , Antígenos de Protozoos/inmunología , Proteínas Protozoarias/inmunología , Toxoplasma/inmunología , Vacunas de ADN/inmunología , Adyuvantes Inmunológicos/administración & dosificación , Animales , Anticuerpos Antiprotozoarios/sangre , Células CHO , Cricetinae , Cricetulus , Femenino , Inmunoglobulina G/biosíntesis , Inmunoglobulina G/sangre , Inyecciones Intramusculares , Interferón gamma/biosíntesis , Interferón gamma/sangre , Liposomas , Modelos Animales , Plásmidos/administración & dosificación , Plásmidos/inmunología , Distribución Aleatoria , OvinosRESUMEN
We and others have established an important role for phosphoinositide-3 kinase gamma (PI3Kgamma) in the chemotactic responses of macrophages and neutrophils. The involvement of this lipid kinase in allergic inflammatory responses is, however, yet to be fully determined. Here we compare wild-type (WT) and PI3Kgamma(-/-) (KO) mice within a model of ovalbumin (OVA) -specific pulmonary inflammation. Upon OVA aerosol challenge, cell influx into the bronchoalveolar lavage (BAL) fluid consisted of neutrophils, macrophages and, more significantly, eosinophils - which are key effector cells in allergic inflammation. Each population was reduced by up to 80% in KO mice, demonstrating a role for PI3Kgamma in cell infiltration into the airways. The mechanism of reduced eosinophilia was analysed within both development and effector stages of the immune response. Comparable levels of OVA-specific T-cell proliferation and immunoglobulin production were established in both strains. Furthermore, no significant differences between WT and KO chemokine production were observed. Having identified the critical point of PI3Kgamma involvement, KO eosinophil chemotactic dysfunction was confirmed in vitro. These data are the first to demonstrate the vital role of PI3Kgamma in acute allergic inflammation. The profound dependency of eosinophils on PI3Kgamma for pulmonary influx identifies this lipid kinase as an attractive target for the pharmacological intervention of asthma.
Asunto(s)
Quimiotaxis de Leucocito/inmunología , Eosinófilos/inmunología , Fosfatidilinositol 3-Quinasas/inmunología , Neumonía/inmunología , Enfermedad Aguda , Animales , Asma/inmunología , Linfocitos B/inmunología , Líquido del Lavado Bronquioalveolar/inmunología , Linfocitos T CD4-Positivos/inmunología , Fosfatidilinositol 3-Quinasa Clase Ib , Citocinas/biosíntesis , Modelos Animales de Enfermedad , Eosinofilia/inmunología , Epítopos de Linfocito T/inmunología , Femenino , Isoenzimas/inmunología , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Noqueados , Ovalbúmina/inmunologíaRESUMEN
Toxoplasmosis caused by an intracellular parasite Toxoplasma gondii is still one of major medical and veterinary problems and there is still need for a vaccine for human toxoplasmosis. Despite years of research much remains to be done to develop effective vaccine. The article presents the current status of vaccine strategies against toxoplasmosis with focus on the most developed approaches using naked DNA and recombinant antigens.
Asunto(s)
Toxoplasmosis/prevención & control , Vacunas de ADN/administración & dosificación , Antígenos de Protozoos/administración & dosificación , Antígenos de Protozoos/inmunología , Antígenos de Protozoos/metabolismo , Humanos , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/inmunología , Proteínas Recombinantes/metabolismo , Vacunas de ADN/inmunologíaRESUMEN
The project's aim is to report a case of Purtscher's retinopathy associated with acute pancreatitis. During the treatment gradual improvement of visual acuity and retina condition have been observed. In the report, the actual views on the pathogenesis of this disease have been discussed.
Asunto(s)
Pancreatitis Alcohólica/complicaciones , Hemorragia Retiniana/etiología , Trastornos de la Visión/etiología , Enfermedad Aguda , Femenino , Humanos , Persona de Mediana Edad , Agudeza VisualRESUMEN
PURPOSE OF REVIEW: To summarize and evaluate critically recent progress with mycobacteria as a potential novel disease modifying treatment strategy in asthma. RECENT FINDINGS: The link between exposure to pathogenic or saprophytic mycobacteria and protection from allergic diseases is still controversial, and recent epidemiological studies, which addressed only exposure to Mycobacterium tuberculosis or bacillus Calmette-Guérin, did not help to clarify this issue. Moreover, the clear efficacy of mycobacterial treatment seen in animal models has not been reproduced in human asthma, and a recent small study testing the hypothesis that heat-killed Mycobacterium vaccae attenuates asthmatic reactions after allergen challenge did not provide convincing results. However, it has been shown that treatment of mice with M. vaccae induces the generation of allergen-specific T regulatory cells capable of suppressing allergen-mediated eosinophilic lung inflammation, suggesting that a general deficiency of T regulatory cell activity might be responsible for the increased prevalence of asthma. This hypothesis is supported by findings that a lack of T regulatory cells, as found in genetic disorders of man and mouse attributable to a mutation of Foxp3, a transcription factor specifically expressed by T regulatory cells, is associated with manifestations of severe atopy and autoimmunity, precisely the spectrum of diseases linked to the hygiene hypothesis. SUMMARY: Further studies on the relationship between mycobacteria and atopic disorders are needed, but there is reason to believe that the novel findings and molecular mechanisms associated with mycobacterial infections will further strengthen the currently unproved therapeutic value of immunotherapy with mycobacteria.
Asunto(s)
Linfocitos T CD4-Positivos/inmunología , Inmunoterapia , Infecciones por Mycobacterium/terapia , Mycobacterium/patogenicidad , Animales , Antibacterianos/uso terapéutico , Asma/terapia , Linfocitos T CD4-Positivos/fisiología , Humanos , Infecciones por Mycobacterium/microbiología , Mycobacterium tuberculosis/patogenicidadRESUMEN
Toxoplasmosis, caused by Toxoplasma gondii, is the major parasitic disease affecting sheep. Infection not only results in significant reproductive losses in these animals, but has public health implications since consumption of infected meat can facilitate zoonotic transmission. Although several serological tests are currently used for diagnosis of ovine toxoplasmosis, production of reliable reagents is a constraint and therefore there is a need to develop new diagnostic tools. In this paper, we assess for the first time, the preliminary diagnostic utility of 19 T. gondii recombinant antigens (GRA1, GRA2ex2, GRA4, GRA5, GRA6, GRA9, SAG1, SAG4, BSR4, P22, ROP1, P36, MIC1ex2, MIC1ex34, MIC3, MAG1, BAG1, LDH1, and LDH2) in immunoglobulin G (IgG) enzyme-linked immunosorbent assays (IgG ELISAs). Following an initial evaluation, eight recombinant antigens (GRA1, GRA9, SAG1, SAG4, P22, MIC1ex2, MIC3, ROP1) were chosen for subsequent testing and comparison against the native Toxoplasma lysate antigen (TLA) in IgG ELISAs using 88 sera from naturally infected sheep and 20 sera from healthy animals. The reactivity of these antigens was variable with the best results for GRA1, P22, ROP1 and TLA. High sensitivity and specificity (100%) was noted for GRA1, ROP1 and TLA; P22 showed a slightly lower sensitivity (98.9%) but the same high specificity (100%). Four different combinations of these antigens (M1: GRA1+ROP1; M2: GRA1+P22; M3: P22+ROP1; M4: GRA1+P22+ROP1) were tested against the same pool of ovine sera; all IgG-positive serum samples were detected by all of the mixtures. However, the most effective for diagnosis of toxoplasmosis in sheep, based on the highest absorbance values, was the mixture M4 containing three proteins. High sensitivity and specificity (100%) was observed from tests containing either M4 or TLA antigens with a new pool of sera (93 seropositive and 35 seronegative). Thus, the present study shows that a cocktail of GRA1+P22+ROP1 recombinant proteins can be used to diagnose T. gondii infection in sheep, and consequently will assist in epidemiological studies.
Asunto(s)
Anticuerpos Antiprotozoarios/sangre , Antígenos de Protozoos/inmunología , Enfermedades de las Ovejas/diagnóstico , Toxoplasma/inmunología , Toxoplasmosis Animal/diagnóstico , Animales , Ensayo de Inmunoadsorción Enzimática/veterinaria , Inmunoglobulina G/sangre , Proteínas Protozoarias/inmunología , Proteínas Recombinantes , Sensibilidad y Especificidad , Pruebas Serológicas/veterinaria , Ovinos , Enfermedades de las Ovejas/parasitología , Toxoplasma/aislamiento & purificación , Toxoplasmosis Animal/parasitologíaRESUMEN
The preliminary diagnostic utility of two mixtures of Toxoplasma gondii recombinant antigens (rROP1+rSAG2 and rROP1+rGRA6) in IgG ELISA and IgG avidity test has been evaluated. A total of 173 serum samples from patients with toxoplasmosis and seronegative people were examined. The sensitivity of IgG ELISA for rROP1+rSAG2 and rROP1+rGRA6 was 91.1% and 76.7%, respectively, while the reactivity for sera from patients where acute toxoplasmosis was suspected was higher, at 100% and 95.4%, respectively, than for people with chronic infection, at 88.2% and 70.6%. In this study a different trend in avidity maturation of IgG antibodies for two mixtures of proteins in comparison with native antigen was observed. The results suggest that a new IgG avidity test using the mixtures of recombinant antigens may be useful for the diagnosis of difficult-to-identify phases of toxoplasmosis. For this reason, selected mixtures after the additional tests on groups of sera with well-defined dates of infection could be used as a better alternative to the native antigens of the parasite in the serodiagnosis of human T. gondii infection.
Asunto(s)
Anticuerpos Antiprotozoarios/inmunología , Afinidad de Anticuerpos , Antígenos de Protozoos , Técnicas de Laboratorio Clínico/métodos , Inmunoglobulina G/inmunología , Toxoplasma/inmunología , Toxoplasmosis/diagnóstico , Antígenos de Protozoos/genética , Ensayo de Inmunoadsorción Enzimática/métodos , Femenino , Humanos , Proteínas de la Membrana/genética , Parasitología/métodos , Embarazo , Proteínas Protozoarias/genética , Proteínas Recombinantes/genética , Sensibilidad y Especificidad , Toxoplasmosis/inmunologíaRESUMEN
Wheat (Triticum aestivum) bran derived polysaccharides, Arabinoxylans (AXs), were evaluated for their immunostimulatory and protective efficacy against Eimeria infection in chickens. Humoral response revealed significantly higher (P<0.05) total Igs, IgG and IgM titers at days 7th and 14th post primary and secondary injections of sheep red blood cells in the experimental chickens administered with AXs as compared to those of control group. The percent protection and daily weight gains were significantly higher (P<0.05) in the chickens of experimental groups as compared to control; whereas, mean oocyst per gram of droppings and lesion scores were significantly higher (P<0.05) in control group as compared to chickens in the experimental groups. The differences in organ body weight ratio of all the lymphoid organs were statistically non-significant (P>0.05) between experimental and control groups except thymus and cecal tonsils. In conclusion, AXs showed both immunostimulatory and protective effects against coccidiosis in broiler chickens.
Asunto(s)
Adyuvantes Inmunológicos/uso terapéutico , Coccidiosis/inmunología , Coccidiosis/prevención & control , Fibras de la Dieta/uso terapéutico , Xilanos/uso terapéutico , Adyuvantes Inmunológicos/aislamiento & purificación , Adyuvantes Inmunológicos/farmacología , Animales , Pollos , Fibras de la Dieta/farmacología , Eimeria/efectos de los fármacos , Eimeria/inmunología , Xilanos/aislamiento & purificación , Xilanos/farmacologíaRESUMEN
CD154 is a cell surface molecule expressed by activated T cells. CD40 and CD154 interaction is critically important in regulating humoral and cell-mediated immune responses. In this study we have investigated whether a DNA vaccine encoding rhoptry protein 1 (ROP1) of Toxoplasma gondii, and encoding ovine CD154 induces an enhanced ROP1-specific immune response in sheep. Two groups of twelve animals received two intramuscular injections, of a DNA plasmid encoding T. gondii ROP1 antigen (group 1) or an ROP1 antigen fused to ovine CD154 (group 2). There were two control groups of sheep. One was injected with an empty vector (group 3) and the other received no injections at all (group 4). The injection of the plasmid containing ROP1 (group 1) at weeks 0 and 4 induced a significant IgG2 response at week 2 which was amplified at week 4 after the booster injection and persisted to week 8 compared to the control animals in groups 3 and 4. For IgG1, significant differences from the control animals were only observed from week 5 onwards. The fusion of CD154 and ROP1 elicited significant IgG1 and IgG2 responses from week 1 which were amplified from weeks 5 to 8 compared to the control animals in groups 3 and 4. The IgG1 response was significantly higher in group 2 animals receiving pROP1-CD154 compared to group 1 receiving pROP1 only. There was no significant difference in IgG2 responses between groups 1 and 2. Significant differences in IFN-γ levels were only observed in treatment group 1 at week 2 and treatment group 2 at weeks 1 and 2 compared to the control animals. The results demonstrated that an intramuscular injection of pROP1-CD154 gene to sheep significantly enhanced their immune response and induced a mixed Th1/Th2 response while the intramuscular injection of pROP1 only induced a Th1-specific immune response.
Asunto(s)
Anticuerpos Antiprotozoarios/sangre , Antígenos de Protozoos/inmunología , Enfermedades de las Ovejas/prevención & control , Toxoplasma/inmunología , Toxoplasmosis Animal/prevención & control , Vacunas de ADN/administración & dosificación , Animales , Antígenos de Protozoos/genética , Ligando de CD40/genética , Ligando de CD40/inmunología , Células CHO , Bovinos , Cricetinae , Cricetulus , Femenino , Inmunización/veterinaria , Inyecciones Intramusculares/veterinaria , Proteínas de la Membrana/genética , Proteínas de la Membrana/inmunología , Nueva Zelanda , Plásmidos , Proteínas Protozoarias/genética , Proteínas Protozoarias/inmunología , Vacunas Antiprotozoos/administración & dosificación , Vacunas Antiprotozoos/inmunología , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/inmunología , Ovinos , Enfermedades de las Ovejas/inmunología , Enfermedades de las Ovejas/parasitología , Oveja Doméstica , Toxoplasma/genética , Toxoplasmosis Animal/inmunología , Toxoplasmosis Animal/parasitología , Vacunas de ADN/inmunologíaRESUMEN
The dense granule proteins of Toxoplasma gondii are investigated as possible vaccine candidates against the parasite. The aim of this research was to evaluate the immune responses of sheep injected twice, intramuscularly, with DNA plasmids encoding T. gondii dense granule antigens GRA1, GRA4, GRA6 and GRA7 formulated into liposomes. Control sheep were injected with an empty vector or received no injections. The injection of sheep with DNA plasmids encoding for GRA1, GRA4, GRA6 or GRA7 elicited an immune response after the first and the second injections as indicated by the moderate to high antibody responses. The injection of pGRA7 induced a significant level of anti-GRA7 IgG2 antibody and IFN-γ responses indicating a Th1-like immune response whereas injection with pGRA1, pGRA4 and pGRA6 stimulated a IgG1 type antibody response with a limited, if any, IFN-γ response. The results demonstrate that the intramuscular injection of sheep with a DNA liposome formulated plasmid coding for GRA proteins is an effective system that induces a significant immune response against T. gondii.
Asunto(s)
ADN Protozoario/inmunología , Proteínas Protozoarias/inmunología , Vacunas Antiprotozoos/inmunología , Enfermedades de las Ovejas/parasitología , Toxoplasma/inmunología , Toxoplasmosis Animal/inmunología , Vacunas de ADN/inmunología , Animales , Anticuerpos Antiprotozoarios/sangre , ADN Protozoario/genética , Ensayo de Inmunoadsorción Enzimática/veterinaria , Femenino , Inmunización/veterinaria , Interferón gamma/sangre , Liposomas/farmacología , Plásmidos/genética , Plásmidos/inmunología , Proteínas Protozoarias/genética , Vacunas Antiprotozoos/administración & dosificación , Vacunas Antiprotozoos/genética , Distribución Aleatoria , Ovinos , Enfermedades de las Ovejas/inmunología , Enfermedades de las Ovejas/prevención & control , Toxoplasma/genética , Toxoplasmosis Animal/parasitología , Toxoplasmosis Animal/prevención & control , Vacunas de ADN/administración & dosificación , Vacunas de ADN/genéticaRESUMEN
The aim of this study is to compare the immune responses of sheep stimulated by the intramuscular injection of a liposome formulated-DNA plasmid encoding the Toxoplasma gondii MAG1 antigen only or co-expressed with ovine IL-6. Forty-five, 2-year-old sheep were divided into four groups. Group 1 received an empty pVAXIg plasmid, group 2 no treatment, group 3 liposome formulated plasmid pVAXIgMAG1 and group 4, pVAXIgMAG1 plus pVAXovIL-6 plasmids. All the animals were inoculated at weeks 0 and 4. The injection of sheep with a plasmid encoding for MAG1 only or a MAG1 plasmid co-expressed with a plasmid encoding for ovine IL-6 produced humoral immune responses. The plasmids containing MAG1 elevated significantly serum IgG1 and IgG2 levels 2 weeks and onwards after the first injection of the plasmids. Co-expression of IL-6 with MAG1 had no effect on IG1 or IG2 levels illustrating that IL-6 in the formulation used had no modulating effect on any measured immune response.
Asunto(s)
Antígenos de Protozoos/inmunología , Inmunización/veterinaria , Interleucina-6/inmunología , Enfermedades de las Ovejas/parasitología , Toxoplasma/inmunología , Toxoplasmosis Animal/inmunología , Animales , Anticuerpos Antiprotozoarios/sangre , Antígenos de Protozoos/genética , Femenino , Inmunización/métodos , Inyecciones Intramusculares/veterinaria , Interferón gamma/sangre , Interleucina-6/genética , Plásmidos/farmacología , Vacunas Antiprotozoos/inmunología , Vacunas Antiprotozoos/normas , Ovinos , Enfermedades de las Ovejas/inmunología , Enfermedades de las Ovejas/prevención & control , Toxoplasma/genética , Toxoplasmosis Animal/parasitología , Toxoplasmosis Animal/prevención & control , Vacunas de ADN/inmunología , Vacunas de ADN/normasRESUMEN
A goal of the current study was to evaluate serological applications of Toxoplasma gondii GRA2 and rhoptry protein 1 (ROP1) antigens. Soluble recombinant GRA2 and ROP1 antigens as fusion proteins containing six histidyl residues at the N and C terminals were obtained using an Escherichia coli expression system. Purification by one-step metal affinity chromatography allowed recovery of milligram amounts of pure recombinant proteins per liter of culture. The usefulness of these antigens for diagnosis of human infections was tested on 167 serum samples obtained during routine diagnostic tests. A panel of 37 serum samples from patients with acute toxoplasmosis was compared to a panel of 90 serum samples from individuals with past infection. The results indicated that both GRA2 and ROP1 recombinant antigens detected antibodies more frequently in samples from individuals with acute infections (100% and 94.6%, respectively) than in samples from individuals with chronic infections (22.5% and 15.5%, respectively). These results suggest that immunoglobulin G antibodies against GRA2 and ROP1 antigens are produced during the acute stage of toxoplasmosis but are uncommon in the chronic phase of the infection. Hence, these recombinant proteins can be used as specific molecular markers to differentiate between acute and chronic infections.
Asunto(s)
Anticuerpos Antiprotozoarios/sangre , Antígenos de Protozoos , Proteínas de la Membrana , Proteínas Protozoarias , Proteínas Recombinantes de Fusión , Toxoplasmosis/diagnóstico , Antígenos de Protozoos/genética , Cromatografía de Afinidad , Escherichia coli/genética , Expresión Génica , Humanos , Inmunoglobulina G/sangre , Proteínas de la Membrana/genética , Proteínas Protozoarias/genética , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/aislamiento & purificaciónRESUMEN
Toxoplasmosis, caused by an intracellular protozoan parasite, Toxoplasma gondii, is widespread throughout the world. The disease is of major medical and veterinary importance, being a cause of congenital disease and abortion in humans and domestic animals. In addition, recently it has gained importance owing to toxoplasma encephalitis in AIDS patients. In the last few years, there has been considerable progress towards the development of a vaccine for toxoplasmosis, and a vaccine based on the live-attenuated S48 strain was developed for veterinary uses. However, this vaccine is expensive, causes side effects and has a short shelf life. Furthermore, this vaccine may revert to a pathogenic strain and, therefore, is not suitable for human use. Various experimental studies have shown that it may be possible to develop a vaccine against human toxoplasmosis. Recent progress in knowledge of the protective immune response generated by T. gondii and the current status of development of a vaccine for toxoplasmosis are highlighted.
Asunto(s)
Vacunas Antiprotozoos/inmunología , Toxoplasma/inmunología , Toxoplasmosis/prevención & control , Animales , Investigación Biomédica/tendencias , HumanosRESUMEN
This paper describes the cloning, purification, and serological applications of matrix antigen MAG1 of Toxoplasma gondii. The expression system used allows the production of a large amount of T. gondii recombinant protein, which was assessed for its potential use in an enzyme-linked immunosorbent assay (ELISA) for detection of T. gondii infection in humans. Serum samples from 117 patients with different stages of infection, along with 10 serum samples from seronegative patients obtained for routine diagnostic tests, were used. The results were compared with those of an ELISA that uses a native T. gondii antigen extract. The MAG1 antigen detected antibodies more frequently from the acute stage (97.3%) than from the chronic stage (7.5%) of toxoplasmosis. Hence, this antigen may be used as a tool for detection of T. gondii immunoglobulin G antibodies in persons with acute toxoplasmosis.
Asunto(s)
Anticuerpos Antiprotozoarios/sangre , Antígenos de Protozoos/inmunología , Proteínas Protozoarias/inmunología , Toxoplasma/inmunología , Toxoplasmosis/diagnóstico , Animales , Ensayo de Inmunoadsorción Enzimática , Humanos , Immunoblotting , Proteínas Protozoarias/genética , Proteínas Protozoarias/aislamiento & purificación , Proteínas Recombinantes/inmunologíaRESUMEN
The present study evaluates immunogenicity and protection potency of a codon-optimized GRA1 DNA vaccine, wild type GRA1 DNA vaccine and an adjuvanted recombinant GRA1 protein vaccine candidate in BALB/c mice against lethal toxoplasmosis. Of the three GRA1 vaccines tested, the recombinant GRA1 protein vaccine results reveal significant increase in immune response and prolonged survival against acute toxoplasmosis compared to DNA vaccinations. Immune response and protection conferred by codon-optimized GRA1 DNA vaccine was slightly better than wild type GRA1 DNA vaccine.
Asunto(s)
Antígenos de Protozoos/inmunología , Toxoplasmosis/prevención & control , Vacunas de ADN/inmunología , Vacunas de Subunidad/inmunología , Secuencia de Aminoácidos , Animales , Antígenos de Protozoos/genética , Secuencia de Bases , Modelos Animales de Enfermedad , Femenino , Ratones , Ratones Endogámicos BALB C , Datos de Secuencia Molecular , Proteínas Recombinantes/inmunología , Toxoplasmosis/inmunología , Vacunas de ADN/genéticaRESUMEN
Laboratory diagnostics of toxoplasmosis depends primarily on serological methods detecting specific antibodies. Since these methods do not always enable specific and sensitive recognition of the infection and phase of toxoplasmosis, the search for new diagnostic tools continues. Recombinant antigens promise a new alternative in diagnostics of Toxoplasma gondii infections. In this work the usefulness of six recombinant T. gondii antigens: GRA1, GRA6, GRA7, p35, SAG1, and SAG2 in the detection of primary murine toxoplasmosis was evaluated. Sera obtained from infected mice differing in their natural susceptibility to T. gondii infection, BALB/c (relatively resistant) and C57BL/6 (relatively susceptible), were tested using ELISA. During acute infection high response to GRA7, GRA6, and p35 antigens was noticed, whereas a strong reactivity with surface antigens SAG1 and SAG2 was characteristic for chronic toxoplasmosis. Our results show that the recombinant antigens are useful in distinguishing between acute and chronic toxoplasmosis regardless of the genetically determined susceptibility of the host.
Asunto(s)
Anticuerpos Antiprotozoarios/sangre , Antígenos de Protozoos/inmunología , Toxoplasma/inmunología , Toxoplasmosis Animal/diagnóstico , Animales , Modelos Animales de Enfermedad , Ensayo de Inmunoadsorción Enzimática/métodos , Humanos , Sueros Inmunes/inmunología , Inmunoglobulina G/sangre , Inmunoglobulina M/sangre , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Proteínas Recombinantes/inmunología , Sensibilidad y EspecificidadRESUMEN
The sphingosine 1-phosphate (S1P) receptor agonist FTY720 is well known for its immunomodulatory activity, sequestering lymphocytes from blood and spleen into secondary lymphoid organs and thereby preventing their migration to sites of inflammation. Because inflammation is critically dependent on a balance between Ag-specific Th/effector cells and T-regulatory cells, we investigated the effect of FTY720 on T-regulatory cell trafficking and functional activity. An increased number of CD4+/CD25+ T cells was found in blood and spleens of FTY720-treated mice, and transfer of these cells resulted in a significantly more pronounced accumulation in spleens but not lymph nodes after treatment, suggesting that this compound differentially affects the homing properties of T-regulatory cells compared with other T cell subsets. Indeed, CD4+/CD25+ T cells express lower levels of S1P1 and S1P4 receptors and demonstrate a reduced chemotactic response to S1P. Moreover, analysis of the functional response of FTY720-treated CD4+/CD25+ T cells revealed an increased suppressive activity in an in vitro Ag-specific proliferation assay. This correlated with enhanced function in vivo, with T-regulatory cells obtained from FTY720-treated mice being able to suppress OVA-induced airway inflammation. Thus, FTY720 differentially affects the sequestration of T-regulatory cells and importantly, increases the functional activity of T-regulatory cells, suggesting that it may have disease-modifying potential in inflammatory disorders.
Asunto(s)
Glicoles de Propileno/farmacología , Receptores de Lisoesfingolípidos/agonistas , Esfingosina/análogos & derivados , Linfocitos T Reguladores/efectos de los fármacos , Animales , Proliferación Celular/efectos de los fármacos , Quimiotaxis de Leucocito/efectos de los fármacos , Clorhidrato de Fingolimod , Inmunosupresores/farmacología , Inflamación/inducido químicamente , Inflamación/tratamiento farmacológico , Ganglios Linfáticos , Activación de Linfocitos/efectos de los fármacos , Activación de Linfocitos/inmunología , Recuento de Linfocitos , Ratones , Ratones Endogámicos C57BL , Especificidad de Órganos , Ovalbúmina , Receptores de Interleucina-2 , Sistema Respiratorio/patología , Esfingosina/farmacología , Linfocitos T Reguladores/fisiologíaRESUMEN
The key role of T helper 2 (Th2) cells in asthma is well established. In contrast, the function of CD8+ T cells producing a distinct cytokine profile similar to Th2 cells is largely unknown. To analyze a potential role of CD8+ T cell subsets, allergen-specific, in vitro-differentiated T cytotoxic (Tc1 or Tc2) cells from T cell receptor transgenic OT-I mice were adoptively transferred into naive C57BL/6 mice. Subsequent allergen challenge of mice injected with Tc1 cells (producing IFN-gamma but no IL-4) resulted in a neutrophilic airway inflammation without induction of bronchial hyperresponsiveness (BHR). In contrast, the inflammatory response of recipients of adoptively transferred Tc2 cells (producing high levels of IL-4 but little IFN-gamma) was characterized by significantly increased numbers of eosinophils and induction of BHR to methacholine. The response of antigen-specific CD8+ T cells to soluble antigen was also observed in an in vitro system. A low concentration of antigen was shown to favor the generation of Tc2 cells, whereas high antigen load resulted in the differentiation of Tc1 cells. Thus, allergen-specific Tc2 cells respond to inhaled soluble antigen, produce an inflammatory response qualitatively similar to Th2 cells and therefore may exacerbate the Th2-driven airway inflammation in asthma.